{"id":818994,"date":"2025-02-27T07:11:02","date_gmt":"2025-02-27T12:11:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-a-business-update\/"},"modified":"2025-02-27T07:11:02","modified_gmt":"2025-02-27T12:11:02","slug":"altimmune-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-a-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-a-business-update\/","title":{"rendered":"Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update"},"content":{"rendered":"
\n

\n Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025<\/em>\n <\/p>\n

\n Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025<\/em>\n <\/p>\n

\n Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications<\/em>\n <\/p>\n

\n Two pharmaceutical industry veterans added to Company Board of Directors<\/em>\n <\/p>\n

\n Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024<\/em>\n <\/p>\n

\n Webcast to be held today, February 27, 2025, at 8:30 a.m. ET<\/em>\n <\/p>\n

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc.<\/a> (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.<\/p>\n

“2024 was a year of important progress for Altimmune as we continued to advance pemvidutide in multiple indications,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “As announced previously, we completed enrollment of the IMPACT Phase 2b trial of pemvidutide in MASH and are on track to report top-line data in the second quarter of 2025. IMPACT was one of the fastest enrolling biopsy-driven Phase 2b MASH trials, which we believe reflects the attractiveness of pemvidutide to patients and providers, specifically the compound’s potent reduction of both liver fat and body weight. Based on the totality of the data generated to date, including multiple non-invasive biomarkers of liver inflammation and fibrosis, we are confident that pemvidutide will achieve statistically significant improvements in biopsy endpoints, both MASH resolution and fibrosis improvement, at trial readout. We anticipate holding an end-of-Phase 2 meeting with FDA by the end of 2025 to gain alignment on the registrational Phase 3 program.”<\/p>\n

Dr. Garg continued, “In-line with our previously stated plan, we submitted INDs for two additional indications in Q4 2024, and I am excited to report that both have received FDA clearance, and we are on track to initiate Phase 2 efficacy studies mid-2025. We look forward to providing information on these additional indications and our development plans during the upcoming virtual R&D Day on March 13. We believe that these indications reinforce our vision for the broad therapeutic utility of pemvidutide.”<\/p>\n

\n
\n Recent Highlights and Anticipated Milestones<\/u>
\n <\/strong>\n <\/p>\n

\n Metabolic Dysfunction-Associated Steatohepatitis (MASH)<\/strong>\n <\/p>\n